Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06679881 · ClinicalTrials.gov registry record · Phase 3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Phase 3 study of Hereditary Angioedema (HAE), sponsored by Pharvaris Netherlands B.V..

Recruiting
Registry status
Phase 3
Development phase
170
Enrollment target
20
Study locations

NCT06679881 is a Phase 3 study of Hereditary Angioedema (HAE) that is actively recruiting participants, run by Pharvaris Netherlands B.V.. The registered enrollment target is 170 participants, above the 43-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (295% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06679881, a Phase 3 study of Hereditary Angioedema (HAE), is actively recruiting participants, sponsored by Pharvaris Netherlands B.V..

RECRUITING
Registry status
Phase 3
Development phase
170 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

Conditions Studied

Hereditary Angioedema (HAE)

Interventions

  • DRUG Deucrictibant

Study Locations (20)

Other

  • Study Site - Melbourne
  • Study Site - Melbourne
  • Study Site - Perth
  • Study Site - Vienna
  • Study Site - Sofia
  • Study Site - Montreal
  • Study Site - Berlin
  • Study Site - Frankfurt
  • Study Site - Hong Kong
  • Study Site - Dublin
  • Study Site - Padua
  • Study Site - Krakow
  • Study Site - Cape Town
  • Study Site - Daegu
  • Study Site - Seoul
  • Study Site - Barcelona
  • Study Site - Brighton

California

  • Study Site - Santa Monica
  • Study Site - Walnut Creek

Missouri

  • Study Site - St Louis

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2025-02-01
Est. Completion 2028-12
Phase Phase 3

Sponsor

Pharvaris Netherlands B.V.

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06679881

The ClinicalTrials.gov registry entry for NCT06679881 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 43-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (295% higher). The listed sponsor is Pharvaris Netherlands B.V., which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 1 intervention - of which Deucrictibant is the first listed.

NCT06679881 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT06679881 about?

NCT06679881 is a clinical study titled "Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE". This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

What is the current status of trial NCT06679881?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2025-02-01. Estimated completion is 2028-12.

What conditions does trial NCT06679881 study?

This clinical trial studies the following conditions: Hereditary Angioedema (HAE).

What interventions are being tested in trial NCT06679881?

The interventions under investigation include: Deucrictibant (DRUG).

Who is sponsoring clinical trial NCT06679881?

This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06679881 being conducted?

This trial has 20 study locations across California, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hereditary Angioedema (HAE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hereditary Angioedema (HAE)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.